WASHINGTON, June 12 /PRNewswire/ -- Novocell, Inc., a stem cell engineering company, presented preliminary data from its phase I/II proof-of-principle clinical trial for encapsulated primary human islet allografts in a late-breaking poster presentation today at the American Diabetes Association’s 66th Scientific Session.
